About this Research Topic
Tuberculosis is a communicable disease that is a major cause of ill health, one of the top 10 causes of death worldwide and the leading cause of death from a single infectious agent (ranking above HIV/AIDS). Globally, an estimated 10.0 million (range, 8.9–11.0 million) people fell ill with TB in 2019. There were an estimated 1.2 million TB deaths among HIV-negative people in 2019, and an additional 208 000 deaths among HIV-positive people.
In accordance with WHO guidelines, detection of MDR/RR-TB requires bacteriological confirmation of TB and testing for drug resistance using rapid molecular tests, culture methods or sequencing technologies. Several propositions have been made to adopt WGS as a diagnostic tool for MTB in the clinical microbiology laboratory. On the other hand, RNASeq, CHIPSeq, CRISPR-Cas or phage-based specialized transduction are transforming functional genomic analysis of the MTB genome to identify novel biomarkers as drug targets and/or for the development of novel vaccines and diagnostics.
Therefore, it is very important to employ new novel tools towards advancing the detection of novel drug targets and biomarkers for vaccine and diagnostics development to be used in fighting or preventing drug resistant TB. There is an urgent need to address the drug-resistant TB crisis to close persistent gaps in care. This research topic will be in line with one of the 10 priority recommendations of the UN Secretary-General's 2020 progress report on TB for actions needed to accelerate progress towards global TB targets.
This research topic aims to address the problem of the emergency of drug resistant TB. The emergence of drug-resistant tuberculosis has complicated M.tb eradication, in particular multidrug-resistant TB. This urgently calls for additional control measures such as characterization of resistant markers, new diagnostic methods, better drugs for treatment, and a more effective vaccine
Given the emerging molecular novel technologies that are becoming available recently, allowing for specific investigations into mutations associated with anti-TB drug resistance at the genomic level and genomic editing; TB biomarkers can be identified for the development of new vaccines and new diagnostic assays together with development of new drugs.
The research topic would like to cover the following themes:
1. Report of the performance of WGS as a diagnostic assay in clinical laboratories
2. TB genomic analysis for identification of diagnostic, drug targets and vaccine marker
3. CRISPR-cas 9 for gene editing of the Mycobacterium Tuberculosis bacterium
4. Evaluation of performance of the new molecular diagnostic TB assay
This research topic will accept several different article types, including mini-reviews, original research and review articles.
Keywords: Tuberculosis, Multi drug-resistance, Whole Genome Sequencing, CRISPR-cas9
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.